用于管理NAFLD炎症的治疗目标和方法
Wanying Geng1,2, Wanying Liao2, Xinyuan Cao2
14+4 Medical Doctor Program, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.
Biomedicines
|February 26, 2025
概括
非酒精性脂肪性肝病 (NAFLD) 和非酒精性脂肪性肝炎 (NASH) 是主要的肝病. 这篇评论强调了炎症.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 免疫学和炎症研究研究
- 代谢和心血管疾病
背景情况:
- 非酒精性脂肪性肝病 (NAFLD) 和其渐进的形式,非酒精性脂肪性肝炎 (NASH),是全球主要的健康负担.
- 炎症是NAFLD/NASH进展的关键驱动因素,有助于肝损伤和纤维化.
- 目前对NAFLD/NASH的治疗方法,包括改变生活方式和现有的药物,显示出有限的疗效,特别是在疾病晚期.
研究的目的:
- 审查目前的治疗目标和策略,以管理NAFLD/NASH的炎症.
- 探索新兴的治疗方法,重点关注炎症,代谢功能障碍和纤维化.
- 强调需要开发新药和组合疗法,以有效管理NAFLD/NASH.
主要方法:
- 本综述综合了有关NAFLD/NASH病原和治疗的当前科学文献.
- 它分析了针对关键炎症途径的新兴治疗策略.
- 该审查讨论了临床管理中的挑战和未来方向.
主要成果:
- 炎症是NAFLD/NASH进展的核心,需要针对性的治疗.
- 新兴的策略侧重于调节炎症,代谢途径和纤维化过程.
- 尽管有前途,但治疗复杂性和患者异质性仍然存在挑战.
结论:
- 有效管理NAFLD/NASH需要解决潜在的炎症.
- 未来的治疗开发应该优先考虑新型抗炎药物和组合疗法.
- 解决NAFLD/NASH的复杂性和异质性对于改善患者的治疗结果至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
89
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
89
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Chronic Pancreatitis II: Collaborative Care
56
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
56
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
294
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
294
Gastritis III: Clinical Manifestations and Management
115
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
115
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
131
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
131


